Latest issue of Haemostaseolgy

| home

The free access does not apply to institutional or commercial use.
Information: claudia.boehm@schattauer.de

Current Issue

Late effects on haemostasis after haematopoietic stem cell transplantation

Journal:	Hämostaseologie
ISSN:	0720-9355
DOI:	http://dx.doi.org/10.5482/ha-1184
Issue:	Issues of 2012 (Vol. 32): Issue 1 2012 (1-86)
Pages:	63-66

Issue

Article

References

Late effects on haemostasis after haematopoietic stem cell transplantation

G. Stussi (1), D. A. Tsakiris (2)

(1) Division of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; (2) Division of Haematology, Department of internal medicine, University Hospital Basel, Switzerland

Summary

Allogeneic and autologous hematopoietic stem cell transplantations are important therapeutic options for patients with hematologic disorders. Hemostatic complications are frequent after hematopoietic stem cell transplantation with a considerable morbidity and mortality. The incidence of bleedings and thrombosis is highest in the first few weeks after transplantation, but may also occur later. However, beyond the first year of transplantation only limited data are available. In long-term survivors the risk for premature atherosclerosis increases over time after allogeneic hematopoietic stem cell transplantation and it is higher than in the age-adjusted general population and in recipients of autologous transplantation.

Keywords

Atherosclerosis, venous thromboembolism, Haemostasis, GvHD

DOI

http://dx.doi.org/10.5482/ha-1184

[Free download]

You may also be interested in...

	1.	Venous thromboembolism in patients with symptomatic atherosclerosis
		See also Editorial by Montecucco, Mach G. Piazza (1), S. Z. Goldhaber (1), D. M. Lessard (2), R. J. Goldberg (2), C. Emery (2), F. A. Spencer (3) Thrombosis and Haemostasis 2011 106 6: 1095-1102 http://dx.doi.org/10.1160/TH11-07-0469

	2.	Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study
		B. Cosmi (1), C. Legnani (1), A. Tosetto (2), V. Pengo (3), A. Ghirarduzzi (4), S. Testa (5), D. Prisco (6), D. Poli (6), A. Tripodi (7), G. Palareti (1) for the PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics) Thrombosis and Haemostasis 2010 103 6: 1152-1160 http://dx.doi.org/10.1160/TH09-11-0759

	3.	Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombinactivatable fibrinolysis inhibitor (TAFI) levels
		Nienke Folkeringa1, Michiel Coppens2, Nic J. G. M. Veeger1, Victor J. J. Bom3, Saskia Middeldorp2, Karly Hamulyak4, Martin H. Prins5, Harry R. Büller2, Jan van der Meer1 Thrombosis and Haemostasis 2008 100 1: 38-44 http://dx.doi.org/10.1160/TH07-11-0659